메뉴 건너뛰기




Volumn 31, Issue 2, 2015, Pages 221-228

How effective are the ESC/EAS and 2013 ACC/AHA guidelines in treating dyslipidemia? Lessons from a lipid clinic

Author keywords

ACC AHA; ESC EAS; Ezetimibe; Guidelines; Lipid lowering treatment; Statins; Treatment goals

Indexed keywords

ATORVASTATIN; COLESEVELAM; EZETIMIBE; FIBRIC ACID DERIVATIVE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OMEGA 3 FATTY ACID; ROSUVASTATIN; TRIACYLGLYCEROL; AZETIDINE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT;

EID: 84923353475     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2014.982751     Document Type: Article
Times cited : (23)

References (26)
  • 1
    • 84862119222 scopus 로고    scopus 로고
    • European guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts
    • Perk J, De Backer G, Gohlke H, et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012;33:1635-701
    • (2012) Eur Heart J 2012 , vol.33 , pp. 1635-1701
    • Perk, J.1    De Backer, G.2    Gohlke, H.3
  • 2
    • 79960539641 scopus 로고    scopus 로고
    • ESC/EAS guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS
    • Reiner Z, Catapano AL, De Backer G, et al. ESC/EAS guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011;32:1769-818
    • (2011) Eur Heart J , vol.32 , pp. 1769-1818
    • Reiner, Z.1    Catapano, A.L.2    De Backer, G.3
  • 3
    • 78049237390 scopus 로고    scopus 로고
    • EUROASPIRE III. Management of cardiovascular risk factors in asymptomatic high-risk patients in general practice: Cross-sectional survey in 12 European countries
    • Kotseva K, Wood D, De Backer G, et al. EUROASPIRE III. Management of cardiovascular risk factors in asymptomatic high-risk patients in general practice: cross-sectional survey in 12 European countries. Eur J Cardiovasc Prev Rehabil 2010;17:530-40
    • (2010) Eur J Cardiovasc Prev Rehabil , vol.17 , pp. 530-540
    • Kotseva, K.1    Wood, D.2    De Backer, G.3
  • 4
    • 84857820914 scopus 로고    scopus 로고
    • Prevalence and risk distribution of residual dyslipidemia in statin-treated patients in Greece
    • Liberopoulos E, Vlasserou F, Mitrogianni Z, et al. Prevalence and risk distribution of residual dyslipidemia in statin-treated patients in Greece. Angiology 2012;63:184-93
    • (2012) Angiology , vol.63 , pp. 184-193
    • Liberopoulos, E.1    Vlasserou, F.2    Mitrogianni, Z.3
  • 5
    • 84897970506 scopus 로고    scopus 로고
    • ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
    • Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 129(25 Suppl 2):S1-S45
    • (2013) Circulation 2014 , vol.129 , Issue.25 , pp. S1-S45
    • Stone, N.J.1    Robinson, J.2    Lichtenstein, A.H.3
  • 7
    • 34548066605 scopus 로고    scopus 로고
    • Statistical modelling of 10-year fatal cardiovascular disease risk in Greece: The HellenicSCORE (a calibration of the ESC SCORE project
    • Panagiotakos DB, Fitzgerald AP, Pitsavos C, et al. Statistical modelling of 10-year fatal cardiovascular disease risk in Greece: the HellenicSCORE (a calibration of the ESC SCORE project). Hellenic J Cardiol 2007;48:55-63
    • (2007) Hellenic J Cardiol , vol.48 , pp. 55-63
    • Panagiotakos, D.B.1    Fitzgerald, A.P.2    Pitsavos, C.3
  • 9
    • 0038645309 scopus 로고    scopus 로고
    • Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial
    • Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol 2003;92:152-60
    • (2003) Am J Cardiol , vol.92 , pp. 152-160
    • Jones, P.H.1    Davidson, M.H.2    Stein, E.A.3
  • 11
    • 19144364305 scopus 로고    scopus 로고
    • National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Adult Treatment Panel III final report. Circulation
    • National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421
    • (2002) Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults , vol.106 , pp. 3143-3421
  • 12
    • 84878360109 scopus 로고    scopus 로고
    • Total lipid management and cardiovascular disease in the Dyslipidemia International Study
    • Ferrieres J, Amber V, Crisan O, et al. Total lipid management and cardiovascular disease in the Dyslipidemia International Study. Cardiology 2013;125:154-63
    • (2013) Cardiology , vol.125 , pp. 154-163
    • Ferrieres, J.1    Amber, V.2    Crisan, O.3
  • 13
    • 79959192888 scopus 로고    scopus 로고
    • LDL cholesterol goals and cardiovascular risk during statin treatment: The IDEAL study
    • Olsson AG, Lindahl C, Holme I, et al. LDL cholesterol goals and cardiovascular risk during statin treatment: the IDEAL study. Eur J Cardiovasc Prev Rehabil 2011;18:262-9
    • (2011) Eur J Cardiovasc Prev Rehabil , vol.18 , pp. 262-269
    • Olsson, A.G.1    Lindahl, C.2    Holme, I.3
  • 14
    • 84865388510 scopus 로고    scopus 로고
    • A comparison of non-HDL and LDL cholesterol goal attainment in a large, multinational patient population: The Lipid Treatment Assessment Project 2
    • Santos RD, Waters DD, Tarasenko L, et al. A comparison of non-HDL and LDL cholesterol goal attainment in a large, multinational patient population: the Lipid Treatment Assessment Project 2. Atherosclerosis 2012;224:150-3
    • (2012) Atherosclerosis , vol.224 , pp. 150-153
    • Santos, R.D.1    Waters, D.D.2    Tarasenko, L.3
  • 16
    • 79956099377 scopus 로고    scopus 로고
    • Comparative efficacy of the addition of ezetimibe to statin vs statin titration in patients with hypercholesterolaemia: Systematic review and meta-analysis
    • Mikhailidis DP, Lawson RW, McCormick AL, et al. Comparative efficacy of the addition of ezetimibe to statin vs statin titration in patients with hypercholesterolaemia: systematic review and meta-analysis. Curr Med Res Opin 2011;27:1191-210
    • (2011) Curr Med Res Opin , vol.27 , pp. 1191-1210
    • Mikhailidis, D.P.1    Lawson, R.W.2    McCormick, A.L.3
  • 17
    • 34548125027 scopus 로고    scopus 로고
    • Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy
    • Mikhailidis DP, Sibbring GC, Ballantyne CM, et al. Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy. Curr Med Res Opin 2007;23:2009-26
    • (2007) Curr Med Res Opin , vol.23 , pp. 2009-2026
    • Mikhailidis, D.P.1    Sibbring, G.C.2    Ballantyne, C.M.3
  • 18
    • 84893648929 scopus 로고    scopus 로고
    • Dyslipidaemia in 2013 new statin guidelines and promising novel therapeutics
    • Mikhailidis DP, Athyros VG. Dyslipidaemia in 2013: new statin guidelines and promising novel therapeutics. Nat Rev Cardiol 2014;11:72-4
    • Nat Rev Cardiol , vol.2014 , Issue.11 , pp. 72-74
    • Mikhailidis, D.P.1    Athyros, V.G.2
  • 19
    • 72049130254 scopus 로고    scopus 로고
    • Meta-analysis of comparative efficacy of increasing dose of atorvastatin versus rosuvastatin versus simvastatin on lowering levels of atherogenic lipids (from VOYAGER
    • Nicholls SJ, Brandrup-Wognsen G, Palmer M, et al. Meta-analysis of comparative efficacy of increasing dose of atorvastatin versus rosuvastatin versus simvastatin on lowering levels of atherogenic lipids (from VOYAGER). Am J Cardiol 2010;105:69-76
    • (2010) Am J Cardiol , vol.105 , pp. 69-76
    • Nicholls, S.J.1    Brandrup-Wognsen, G.2    Palmer, M.3
  • 21
    • 84866684691 scopus 로고    scopus 로고
    • Targeting cardiovascular risk: The impact of age, gender and compliance to treatment
    • Kostapanos MS, Elisaf MS, Mikhailidis DP. Targeting cardiovascular risk: the impact of age, gender and compliance to treatment. Curr Med Res Opin 2012;28:1415-19
    • (2012) Curr Med Res Opin , vol.28 , pp. 1415-1419
    • Kostapanos, M.S.1    Elisaf, M.S.2    Mikhailidis, D.P.3
  • 22
    • 0037167013 scopus 로고    scopus 로고
    • Adherence with statin therapy in elderly patients with and without acute coronary syndromes
    • Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 2002;288:462-7
    • (2002) JAMA , vol.288 , pp. 462-467
    • Jackevicius, C.A.1    Mamdani, M.2    Tu, J.V.3
  • 23
    • 84860798384 scopus 로고    scopus 로고
    • Genetic determinants of statininduced low-density 1420 lipoprotein cholesterol reduction: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) trial
    • Chasman DI, Giulianini F, MacFadyen J, et al. Genetic determinants of statininduced low-density 1420 lipoprotein cholesterol reduction: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial. Circ Cardiovasc Genet 2012;5:257-64
    • (2012) Circ Cardiovasc Genet , vol.5 , pp. 257-264
    • Chasman, D.I.1    Giulianini, F.2    Macfadyen, J.3
  • 24
    • 84893325766 scopus 로고    scopus 로고
    • More than a billion people taking statins? Potential implications of the new cardiovascular guidelines
    • Ioannidis JP. More than a billion people taking statins?: Potential implications of the new cardiovascular guidelines. JAMA 2014;311:463-4
    • (2014) JAMA , vol.311 , pp. 463-464
    • Ioannidis, J.P.1
  • 25
    • 84898950294 scopus 로고    scopus 로고
    • The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: The good the bad and the uncertain: A comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011
    • Ray KK, Kastelein JJ, Matthijs Boekholdt S, et al. The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011. Eur Heart J 2014;35:960-8
    • (2014) Eur Heart J , vol.35 , pp. 960-968
    • Ray, K.K.1    Kastelein, J.J.2    Matthijs Boekholdt, S.3
  • 26
    • 84906840082 scopus 로고    scopus 로고
    • The 2013 american college of cardiology/american heart association guidelines for the treatment of dyslipidemia: Mind the gaps!
    • Athyros VG, Katsiki N, Karagiannis A, et al. The 2013 American College of Cardiology/American Heart Association guidelines for the treatment of dyslipidemia: mind the gaps! Curr Med Res Opin 2014;30(9):1-5
    • (2014) Curr Med Res Opin , vol.30 , Issue.9 , pp. 1-5
    • Athyros, V.G.1    Katsiki, N.2    Karagiannis, A.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.